Fri, Aug 1, 2014, 8:23 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Trius Therapeutics, Inc. (TSRX) Message Board

  • chimakot chimakot Mar 14, 2013 2:46 PM Flag

    ESTABLISH-2 Results Imminent.

    This is an excerpt from the POPthink SA article just released.
    ESTABLISH-2 Results Imminent

    As noted above, Trius completed enrollment in the second Phase III study, ESTABLISH-2, on Dec. 10, 2012. We remind investors that ESTABLISH-1 completed enrollment on Sept. 15, 2011, and reported top-line data 95 days later on Dec. 19, 2011. Assuming a similar timeline, 95 days after Dec. 10, 2012, would be March 15, 2013. We suspect that compiling data from ESTABLISH-2 (118 clinical sites globally) will take an extra week compared to ESTABLISH-1 (84 clinical sites globally). We also note ESTABLISH-2 had far more sites outside the U.S., thus we are expecting data the last week of March 2013.

    We remain optimistic on the results of ESTABLISH-2, believing that tedizolid will demonstrate non-inferiority to linezolid on the primary endpoint of response rate, defined as cessation of spread and absence of fever at 48-72 hours. We outlined our bullish thesis on Trius in December 2012.

    Let's Ride!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
13.630.00(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.